Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04439890
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status Recruiting
Phase Phase 3
Start date August 8, 2019
Completion date December 31, 2021